Donald Neff, MD
Urology · Kansas City, MONPI 1871766162
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (41.2%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 20 manufacturers reported payments, led by Boston Scientific at 35.9% of the total. Among urology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 95 payments — averaging $284.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$10K
- KARL Storz Endoscopy-america$8K
- Procept Biorobotics Corporation$5K
- Lumenis, Inc$3K
- Teleflex LLC$606
- Cook Medical LLC$306
- plus $790 from 14 others
Across 14 payments — averaging $8109.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boston Scientific$86K
- Olympus Corporation Of The Americas$28K
What the payments were for
- Consulting fees$2,68110%
- Speaking & faculty fees$11,10541%
- Travel & lodging$9,66536%
- Food & beverage$3,53513%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 31 | $9,692 |
| KARL Storz Endoscopy-america | 8 | $7,741 |
| Procept Biorobotics Corporation | 31 | $4,623 |
| Lumenis, Inc | 2 | $3,227 |
| Teleflex LLC | 1 | $606 |
| Cook Medical LLC | 2 | $306 |
| Olympus America Inc. | 3 | $225 |
| Axonics, Inc. | 2 | $184 |
| Merck | 1 | $87 |
| Johnson & Johnson | 1 | $49 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $40 |
| Integra Lifesciences Corporation | 2 | $39 |
| Coloplast | 2 | $27 |
| Medtronic(2 entities) | 2 | $27 |
| Hollister Incorporated | 1 | $27 |
| Astellas Pharma US Inc | 1 | $18 |
| Bayer | 1 | $18 |
| Rochester Medical Corporation | 1 | $17 |
| Baxter Healthcare | 1 | $16 |
| Convatec Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- N/A$6,532
- Moses 550 D\F\L$5,999
- Lumenis Pulse 120H$4,365
- AquaBeam Robotic System$3,033
- GENERAL BPH$1,240
- AQUABEAM SYSTEM$1,096
- AUTOCON$786
- UroLift$606
- Xpeeda DSL Fiber$200
- LITHO 150$188
- GENERAL - THERAPIES$165
- Bulkamid$140
- Axonics$140
- AMS 700$119
- Cook$118
- Lumenis Pulse 50H$100
How this compares
$26,986 in reported general payments places this provider in the 90th percentile of 250 urology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 89 | $68,691 |
| MyrbetriqMirabegron | 76 | $53,706 |
| Tamsulosin Hcl | 351 | $5,542 |
| Trospium Chloride | 68 | $4,171 |
| Finasteride | 295 | $3,809 |
| Tadalafil | 19 | $3,010 |
| Methenamine Hippurate | 22 | $2,437 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 79 | $2,170 |
| Silodosin | 20 | $1,316 |
| Oxybutynin Chloride ErOxybutynin Chloride | 19 | $588 |
| Dutasteride | 17 | $458 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 23 | $414 |
| Solifenacin Succinate | 14 | $411 |
| Oxybutynin Chloride | 14 | $329 |
| Cefdinir | 18 | $211 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $18 | $53,70676 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 250 urology providers in Missouri.
Other urology in Kansas City
- Samuel KuykendallKansas City$141K
- Lukas HockmanKansas City$14K
- Patrick ProbstKansas City$14K
- Daniel HolmesKansas City$9K
- Travis BullockSaint Louis$201K
- Michael JohnsonSaint Louis$160K
- Gerald ParkNorth Kansas City$136K
- Gurdarshan SandhuSaint Louis$101K
- Etai GoldenbergSt. Louis$95K
- Gregory McLennanSaint Louis$89K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.